跳至主要内容
临床试验/TCTR20220821001
TCTR20220821001Unknown3 期

The efficacy and safety of mosapride compared with domperidone in Parkinsons disease with gastroparesis; A randomized, double blind, double dummy study

Faculty of Medicine, Prince of Songkla University0 个研究点目标入组 60 人开始时间: 2022年8月21日最近更新:
适应症

试验速览

阶段
3 期
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20 Years 至 80 Years(—)
性别
All

入选标准

  • Parkinson's disease patients with clinical suspected gastroparesis including nausea, vomiting, abdominal distension, early satiety, abdominal pain
  • or whom taking prokinetic due to these symptoms

排除标准

  • Severe dysphagia or mastication problems causing eating problems
  • Underlying diseases of diabetes mellitus, hypothyroidism, connective tissue disease, chronic kidney disease (eGFR < 30 ml/min/1.73mm2)
  • History of stomach or proximal small bowel surgery
  • History of polymorphic ventricular tachycardia
  • QTc prolongation from ECG (QTc > 450 msec for male or > 470 msec for female
  • History of egg allergy (used for gastric scintigraphy test)
  • History of mosapride or domperidone allergy

研究者

发起方
Faculty of Medicine, Prince of Songkla University

相似试验